Shingo Hatakeyama, MD, of the Hirosaki University Graduate School of Medicine in Hirosaki, and colleagues reviewed the oncologic outcomes of pT1NOMO RCC detected by annual computed tomography (CT) screening. The study population consisted of 119 patients with incidentally detected pT1NOMO RCC: 13 HD patients and 106 age-matched patients without renal dysfunction (controls). Cancer-specific survival rates were 92% and 95% in the HD patients and controls, respectively, a nonsignificant difference between the groups. Overall five-year survival rates did differ significantly: 54% vs. 96%.
The researchers concluded that their study provides no evidence of the oncologic effectiveness of annual CT screening for HD patients.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.